|When:||« Back to Calendar November 17, 2011 @ 2:00 pm - 6:00 pm|
|Where:||Nutter Conference Center
155 Seaport Blvd
|Add to Calendar Add to Google Cal|
|Categories:||Other Events of Interest|
An outstanding line-up of speakers is being assembled for this conference including representatives of Atlas Venture, GlaxoSmithKline (GSK), Novartis, Smith and Nephew, Longwood Founders Fund, and Pfizer. Two panel discussions will examine issues and trends in early-stage development among life science companies.
The first panel will seek to answer the question “How Lean is Too Lean?” and will consider some of the pitfalls and challenges faced by development stage life science companies as they execute on a lean business model from raw technology through the clinical and operational phases of development and finally to commercial launch. The second panel asks “Are Big Pharma and Big Device the New Development Accelerators?” and will examine how large companies are deploying new external investment and development models to optimize their “buy” and “build” pipelines.
Presented by Nutter McClennen & Fish LLP
Co-Presented by Halloran Consulting Group and PwC
More information: www.acceleration.nutter.com/2011